Support: 888-992-3836 Home NewsWire Subscriptions
InvestorsHub Logo
Login/Register
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Erasca Inc (ERAS)

  7. Erasca Inc (ERAS) Financials

ERAS

Erasca Inc
3.18
0.22 (7.43%)
Upgrade to Real-Time

Erasca Inc. (ERAS) Fundamentals
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes two clinical-stage programs (ERK and SHP2 inhibitors), two preclinical-stage programs (CNS-penetrant KRAS G12C and EGFR inhibitors), and seven discovery-stage programs targeting other key oncogenic drivers.
SHARE INFORMATION
Market Cap$ 412,613,811
Shares Outstanding150,588,982
Float105,602,059
Percent Float70.13%
Short Interest0.00
Short Percent Float0.0%
Short Interest Ratio0.00
Short Interest Date-
Latest Fiscal Dividend Per Share$ 0.00
Latest Fiscal Revenue$ 0
Latest Fiscal EPS$ -1.99
Latest Fiscal Date2022-12-31
DIVIDENDS
Dividend (3 Years)$ 0.00
Dividend (5 Years)$ 0.00
Ex Dividend Date-
Dividend Rate$ 0.00
Dividend Yield0.0%
Payment Cash-
HOLDERS
Institutions263
Institutional Holdings Date2023-02-28
Institutional Bought Previous 3 Months10,502,107
Institutional Holdings Percent75.6%
Institutional Sold Previous 3 Months23,473,932
Insider Holdings Date2023-02-28
Insider Bought Previous 3 Months3,931,274
Insider Holdings Percent0.9
Insider Sold Previous 3 Months2,000,006
Insider Shares Owned1,371,680
TRADING INFO
52 Week High$ 10.74
52 Week Low$ 2.65
52 Week High Change$ -71.55
21 Day Moving Average$ 3.1636
21 Day Extended Moving Average$ 3.1451
50 Day Moving Average$ 3.5923
50 Day Extended Moving Average$ 3.6569
200 Day Moving Average$ 6.1648
200 Day Extended Moving Average$ 6.1467
10 Day Average Volume1,489,475
20 Day Average Volume1,297,133
30 Day Average Volume1,131,975
50 Day Average Volume1,062,224
Alpha-0.065270
Beta1.1860
Standard Deviation0.192518
R20.138053
7 Day Price Change$ -0.39
7 Day Percent Change-12.46%
21 Day Price Change$ -0.70
21 Day Percent Change-20.35%
30 Day Price Change$ -0.86
30 Day Percent Change-23.89%
Month to Date Price Change$ -0.86
Month to Date Percent Change-23.89%
Quarter to Date Price Change$ -1.57
Quarter to Date Percent Change-36.43%
180 Day Price Change$ -5.61
180 Day Percent Change-67.19%
200 Day Price Change$ -5.76
200 Day Percent Change-67.76%
Year to Date Price Change$ -1.57
Year to Date Percent Change-36.43%

Erasca Inc. (ERAS) Key Ratios

PROFITABILITY
EBIT Margin0.0%
EBITDA Margin0.0%
Pre-Tax Profit Margin0.0%
Profit Margin Count0.0%
Gross Margin0.0%
Profit Margin TOT0.0%
INCOME STATEMENTS
Revenue$ 0
Revenue Per Share$ 0.00
Revenue (3 Years)$ 0.00
Revenue (5 Years)$ 0.00
FINANCIAL STRENGTH
Price to Tangible Book1.00
Total Debt To Equity0.10
Int Coverage0.00
Current Ratio9.10
Leverage Ratio1.20
Quick Ratio8.90
Long Term Debt To Capital0.12
VALUATION MEASURES
PE Ratio-4.20
Enterprise Value$ 45,644,819
Price to Sales0.00
Price to Free Cash-3.60
PE High Last 5 Years0.00
Price To Book1.00
Price To Cash Flow0.00
PE Low Last 5 Years0.00
Price to Tangible Book1.00
MANAGEMENT EFFECTIVENESS
Receivables Turnover0.00
Invoice Turnover0.00
Assets Turnover0.00
Return Assets-47.78
Return on Equity-55.92
Return on Capital-30.36

Erasca Inc. (ERAS) Profile

PROFILE INFO
Issue TypeCS
SEC Type-
AuditorKPMG LLP
CEOJonathan E. Lim
Emplyoees129
Last AuditUQ
CIK0001761918
IndustryBiotechnology
SectorHealthcare
NAICSResearch and Development in Biotechnology (except Nanobiotechnology)(541714)
CONTACT INFO
Address10835 Road to the Cure
Suite 140
San Diego, CA 92121
Websitehttps://www.erasca.com
Facsimile-
Telephone+1 858 465-6511
Email-


Your Recent History
NASDAQ
ERAS
Erasca
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to InvestorsHub
Register Now

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.